Program Overview
The Novel Therapeutics Delivery program is part of the MLSC’s Accelerating Research through Collaboration (ARC) Awards. This program fosters the development of novel technologies and techniques for the delivery of existing or innovative therapies by working at the intersection of engineering, biology, chemistry, and medicine. Specifically, it strives to capitalize and incentivize translational projects to address complex challenges in “therapeutic” delivery – from biomanufacturing, to targeted delivery, to biomaterials and more.
Up to $5 million capital dollars are available for the current program round, with each award anticipated to be up to $750,000 to support equipment and other capital expenses at not-for-profit partners.
The application period will run from Aug. 4 – Nov. 21, 2025 at 1 p.m. EST.
Eligibility & Evaluation
Eligibility criteria include multiple factors, such as applicants must be a Massachusetts legally organized “not-for-profit” entity such as an academic/research institution, a hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.
Please view the full list of eligibility requirements and evaluation process.
Resources
Post-award deliverables, confidentiality, and general conditions
- Please note that the submission system only allows one active application per grant program at a time for each user account. It is possible to have an active application across multiple programs, as well as submit applications for the same program sequentially.
R.E.D.: Research Equipment Database
D.A.T.A. (Databases, Algorithms, Tools, and Analyses) Repository
Impact on the Ecosystem
Innovative new therapies are dependent on advancements in drug delivery. Increased drug complexity, the rise of biopharmaceuticals, novel therapeutic technologies, bioavailability challenges, and the demand for the demonstration of strong drug performance are all driving unprecedented technology innovation; however, the availability of such therapies is not accelerating at the rate with which technology is advancing. Existing therapies can also benefit from improved delivery methods and devices, increasing patient compliance and improving overall health. Over the past six years, the MLSC has awarded $14.7 million in capital funding through the Novel Therapeutics Delivery program.
Learn more about the 2020, 2021, 2022, 2023, and 2024 Novel Therapeutics Delivery awardees, including the principal investigator, industry partners, and the innovative projects.
Connect with Us to Learn More
If you have any questions regarding the application process, e-mail: DrugDelivery@Masslifesciences.com.
